BioSpace News Archive

Drug Development

Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of Sickle Cell DiseaseIND filing for novel genome editing medicine by end of 2020

Editas Medicine, Inc., a leading genome editing company, announced results from a pre-clinical, proof-of-concept study of EDIT-301.

June 12, 2020
·
5 min read
Deals

GlySens Incorporated Closes Incremental $15 Million Financing Supporting On-Going Clinical Evaluations and First-in-Man Study of the Third Generation Eclipse® 3 ICGM® System

GlySens Incorporated announced that the company has closed on an incremental $15M financing.

June 12, 2020
·
3 min read
ams and Senova Join Efforts on Technology to Create Point-of-care Rapid Antibody Test for COVID-19

ams announced they have successfully concluded tests using a combination of Senova technology and ams spectral sensor technology to improve performance and usability of a lateral flow-based test to detect antibodies related to the COVID-19 virus.

June 12, 2020
·
5 min read
Job Trends

Magellan Health, Inc. Notifies Consumers of Data Security Incident

Magellan Health, Inc. and its subsidiaries and affiliates (“Magellan”) recently discovered a ransomware attack. We are providing notice of this incident, along with background information of the incident and steps that those affected can take.

June 12, 2020
·
2 min read
Drug Development

Aptose Presents Early Phase 1a/b CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

Safety, tolerability and phospho-BTK inhibition at first three CG-806 dose levels in patients with CLL and other B-cell malignancies

June 12, 2020
·
7 min read
Drug Development

Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress

Showed statistically significant increase in red blood cells containing fetal hemoglobin (F-cells) and dose-dependent increase in fetal hemoglobin percentage in high-dose group after 24 weeks of monotherapy

June 12, 2020
·
8 min read
Drug Development

Forma Therapeutics Presents Safety, Pharmacokinetic and Pharmacodynamic Data from Phase 1 Clinical Trial for Investigational Agent FT-4202 in Patients with Sickle Cell Disease

Findings indicate favorable tolerability profile and favorable pharmacokinetic and pharmacodynamic effects in patients with SCD following a single dose of FT-4202

June 12, 2020
·
5 min read
Drug Development

Scholar Rock Presents Clinical and Preclinical Data for SRK-015 at the 2020 Virtual Cure SMA Research and Clinical Care Meeting

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced two presentations as part of the 2020 Virtual Cure SMA Research and Clinical Care Meeting.

June 12, 2020
·
5 min read
Business

Vireo Health Announces Resignation of Bruce Linton as Board Member

Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), a leading physician-led, science-focused, multi-state cannabis company, today announced Bruce Linton resigned yesterday from the Company’s board of directors.

June 12, 2020
·
3 min read
Biotech Beach

Cue Health Receives FDA Emergency Use Authorization for Its Rapid, Portable, Molecular Point-of-Care COVID-19 Test

Cue Health Inc. (“Cue”), a healthcare technology company, announced today that it has received Emergency Use Authorization (“EUA”) from the U.S. Food and Drug Administration (“FDA”) for the company’s rapid, portable, point-of-care COVID-19 test.

June 12, 2020
·
3 min read